Ali Murat Tatlı

488 total citations
47 papers, 281 citations indexed

About

Ali Murat Tatlı is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ali Murat Tatlı has authored 47 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Ali Murat Tatlı's work include Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (5 papers) and Cancer Diagnosis and Treatment (5 papers). Ali Murat Tatlı is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (5 papers) and Cancer Diagnosis and Treatment (5 papers). Ali Murat Tatlı collaborates with scholars based in Türkiye, United States and India. Ali Murat Tatlı's co-authors include Mükremın Uysal, Hasan Şenol Çoşkun, Sema Sezgin Göksu, Şeyda Gündüz, Hakan Bozcuk, Burhan Savaş, Mustafa Özdoğan, Dilek Ünal, Deniz Tural and Didem Taştekin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biomedicine & Pharmacotherapy.

In The Last Decade

Ali Murat Tatlı

42 papers receiving 276 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Murat Tatlı Türkiye 10 123 69 64 45 43 47 281
Emel Ebru Pala Türkiye 11 62 0.5× 51 0.7× 71 1.1× 37 0.8× 42 1.0× 44 335
Jason Yap United Kingdom 10 89 0.7× 43 0.6× 113 1.8× 88 2.0× 63 1.5× 34 523
Salma Khan Pakistan 8 83 0.7× 68 1.0× 101 1.6× 26 0.6× 13 0.3× 27 285
Sema Sezgin Göksu Türkiye 11 206 1.7× 113 1.6× 66 1.0× 51 1.1× 29 0.7× 52 355
Mary Nguyen-Nielsen Denmark 10 107 0.9× 121 1.8× 32 0.5× 35 0.8× 26 0.6× 13 389
A. Thanos Greece 9 65 0.5× 80 1.2× 102 1.6× 42 0.9× 17 0.4× 26 303
Olga van der Hel Netherlands 9 78 0.6× 49 0.7× 59 0.9× 58 1.3× 37 0.9× 10 370
A Hartmann Brazil 12 70 0.6× 90 1.3× 145 2.3× 41 0.9× 37 0.9× 42 374
Ryo Atsuta Japan 13 45 0.4× 160 2.3× 47 0.7× 41 0.9× 17 0.4× 31 437
Yun Hwa Jung South Korea 9 66 0.5× 39 0.6× 35 0.5× 42 0.9× 34 0.8× 29 221

Countries citing papers authored by Ali Murat Tatlı

Since Specialization
Citations

This map shows the geographic impact of Ali Murat Tatlı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Murat Tatlı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Murat Tatlı more than expected).

Fields of papers citing papers by Ali Murat Tatlı

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Murat Tatlı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Murat Tatlı. The network helps show where Ali Murat Tatlı may publish in the future.

Co-authorship network of co-authors of Ali Murat Tatlı

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Murat Tatlı. A scholar is included among the top collaborators of Ali Murat Tatlı based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Murat Tatlı. Ali Murat Tatlı is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bılıcı, Ahmet, Özcan Yıldız, Saadettin Kılıçkap, et al.. (2025). Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina. 61(4). 638–638. 1 indexed citations
2.
Yılmaz, Mesut, et al.. (2025). Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey. Medicina. 61(6). 951–951. 1 indexed citations
3.
Başsorgun, Cumhur İbrahim, et al.. (2025). Evaluation of tumor budding, desmoplastic reaction, and lymphocytic infiltration in predicting survival for pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology. 17(6). 107021–107021.
4.
Koçak, Mehmet Zahid, Çağlayan Geredeli, Ali Murat Tatlı, et al.. (2024). The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients. Future Oncology. 20(38). 3099–3105. 2 indexed citations
5.
6.
Koçak, Mehmet Zahid, et al.. (2023). The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study. Journal of Cancer Research and Clinical Oncology. 149(11). 9183–9189. 2 indexed citations
7.
Göksu, Sema Sezgin, et al.. (2023). Granulosa Cell Tumor of the Ovary in a Patient with Adjuvant Tamoxifen Use for Breast Cancer: An Extremely Rare Case Report. Acta Oncologica Turcica. 56(2). 180–184. 1 indexed citations
8.
Akagündüz, Baran, Deniz Can Güven, Muhammet Özer, et al.. (2022). Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer. Journal of Geriatric Oncology. 14(2). 101367–101367.
9.
Geredeli, Çağlayan, et al.. (2022). The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer. European Journal of Clinical Pharmacology. 79(2). 243–248. 13 indexed citations
10.
Tatlı, Ali Murat, Çağlayan Geredeli, Ali Ayberk Beşen, et al.. (2021). Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. Cancer Chemotherapy and Pharmacology. 88(5). 805–812. 1 indexed citations
11.
Telli, Tuğba Akın, et al.. (2019). Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 83(6). 1137–1145. 1 indexed citations
12.
Arıkan, Fatma, et al.. (2019). Fertility in testicular cancer patients: a single-centre study in Turkey. International Journal of Clinical Oncology. 25(3). 495–500. 4 indexed citations
13.
14.
Gündüz, Şeyda, Sema Sezgin Göksu, Ali Murat Tatlı, et al.. (2015). Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Molecular and Clinical Oncology. 3(5). 1109–1112. 22 indexed citations
15.
Taştekin, Didem, Mehmet Karabulut, Makbule Tambaş, et al.. (2014). Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients. Tumor Biology. 35(12). 11871–11877. 5 indexed citations
16.
Gündüz, Şeyda, Hasan Mutlu, Sema Sezgin Göksu, et al.. (2014). Oral Cyclophosphamide and Etoposide in Treatment of Malignant Pleural Mesothelioma. Asian Pacific Journal of Cancer Prevention. 15(20). 8843–8846. 3 indexed citations
17.
Gündüz, Şeyda, Dilek Ünal, Mükremın Uysal, et al.. (2014). Use of chemotherapy at the end of life in Turkey. BMC Palliative Care. 13(1). 51–51. 17 indexed citations
18.
Uysal, Mükremın, Hakan Bozcuk, Sema Sezgin Göksu, et al.. (2013). Pesticides and Cancer: The First Incidence Study Conducted in Turkey. Journal of Environmental Pathology Toxicology and Oncology. 32(3). 245–249. 10 indexed citations
19.
Tatlı, Ali Murat, et al.. (2013). Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. Urologia Internationalis. 94(3). 363–365. 5 indexed citations
20.
Tatlı, Ali Murat, Mükremın Uysal, Sema Sezgin Göksu, et al.. (2011). Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen. Medical Oncology. 29(3). 1935–1937. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emel Ebru Pala Breakdown of academic impact, for papers by Jason Yap Breakdown of academic impact, for papers by Salma Khan Breakdown of academic impact, for papers by Sema Sezgin Göksu Breakdown of academic impact, for papers by Mary Nguyen-Nielsen Breakdown of academic impact, for papers by A. Thanos Breakdown of academic impact, for papers by Olga van der Hel Breakdown of academic impact, for papers by A Hartmann Breakdown of academic impact, for papers by Ryo Atsuta Breakdown of academic impact, for papers by Yun Hwa Jung
Rankless by CCL
2026